Therapeutic Asset Ratings

329 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Fludarabine Melanoma	Beijing Biotech	P2	B (62)
Atezolizumab Melanoma	National Cancer Institute (NCI)	P3	B (61)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER Melanoma	M.D. Anderson Cancer Center	P3	B (61)
Calcium folinate pentahydrate Melanoma	Neonc Technologies, Inc.	P2	B (61)
Docetaxel Melanoma	NuCana plc	P2	B (61)
Durvalumab Melanoma	AstraZeneca	P2	B (61)
Eloxatin Melanoma	Pfizer	P2	B (61)
PREDNISONE TABLETS Melanoma	National Cancer Institute (NCI)	P2	B (61)
Ribociclib Melanoma	Melanoma Institute Australia	P2	B (61)
Binimetinib Melanoma	The Christie NHS Foundation Trust	P3	B (60)
Encorafenib Melanoma	The Christie NHS Foundation Trust	P3	B (60)
Prolgolimab Melanoma	Biocad	P3	B (60)
Sorafenib Melanoma	Charite University, Berlin, Germany	P3	B (60)
Vibostolimab Melanoma	Merck Sharp & Dohme LLC	P3	B (59)
Imatinib Melanoma	University of California, San Francisco	P2	B (59)
Pegylated Interferon Α-2B Melanoma	Hassane M. Zarour, MD	P2	B (59)
Axitinib Melanoma	Peking University Cancer Hospital & Institute	P2	B (58)
Palbociclib Melanoma	Peter MacCallum Cancer Centre, Australia	P2	B (58)
ro7247669 Melanoma	Hoffmann-La Roche	P2	B (58)
Inno-206 Melanoma	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P2	B (57)
TRASTUZUMAB Melanoma	Ascendis Pharma Oncology Division A/S	P2	B (57)
Lipitor Melanoma	Erasmus Medical Center	P4	B (56)
Bcd-217 Melanoma	Biocad	P3	B (56)
Fianlimab Melanoma	M.D. Anderson Cancer Center	P3	B (56)
Intismeran Melanoma	Merck Sharp & Dohme LLC	P3	B (56)

Showing 26 to 50 of 329 assets

PreviousPage 2 of 14Next